Tvardi Therapeutics, Inc. revenue by segment TVRD

Annual Quarterly

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2025 Mar 31, 2025	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	8	—	7	21	42	23	135	20	13	1	0
Other Revenue Non Cash	—	—	4 +519.0% share 60.6%	1 share 3.3%	—	—	—	—	—	—	—
Collaborative Revenue	—	—	2 -83.9% share 29.2%	13 -21.9% share 61.7%	17 +2247.3% share 39.6%	1 share 3.1%	—	—	—	—	—
License And Milestone Fees	—	—	—	1 -93.9% share 4.3%	15 -29.3% share 35.8%	21 -84.2% share 92.2%	134 +580.8% share 99.5%	20 share 99.3%	—	—	—
Commercial Supply Revenue	—	—	1 -89.0% share 9.0%	6 -42.8% share 27.9%	10 +1358.3% share 24.4%	1 share 3.0%	—	—	—	—	—
Royalty	—	—	—	0 +476.4% share 2.0%	0 share 0.2%	—	—	—	—	—	—
Clinical Compound Revenue	—	—	0 -49.1% share 1.2%	0 share 0.8%	—	0 -38.1% share 1.7%	1 +359.3% share 0.5%	0 share 0.7%	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: TVRD (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Sugar Land, TX
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1346830
Former names: Cara Therapeutics, Inc. (until Apr 11, 2025); Cara Therapeutics Inc (until Jul 21, 2010)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.